论文部分内容阅读
目的观察尿激酶胸膜腔灌注治疗结核性和类肺炎性包裹性胸腔积液的临床疗效。方法将123例包裹性胸腔积液患者按病因不同分成结核性包裹性胸腔积液组63例,类肺炎性包裹性胸腔积液组60例。两组患者在给予抗结核或抗炎等综合治疗基础上,加用尿激酶胸膜腔灌注治疗,疗程结束后评价临床疗效。结果结核性包裹性胸腔积液组:显效41例,有效20例,无效2例,总有效率为96.83%;类肺炎性包裹性胸腔积液组:显效36例,有效17例,无效7例,总有效率为88.33%。两组患者均取得良好的临床疗效,类肺炎性包裹性胸腔积液组疗效稍差于结核性包裹性胸腔积液组,两组临床疗效经χ2检验差异无统计学意义(χ2=3.2718,P>0.05)。结论尿激酶胸膜腔灌注治疗结核性或类肺炎性包裹性胸腔积液均能取得良好的临床疗效,两组疗效差异不大。
Objective To observe the clinical efficacy of pleural fluid infusion of urokinase in the treatment of tuberculous and pneumocytic pleural effusion. Methods A total of 123 patients with pleural effusion were divided into tuberculous pleural effusion group (63 cases) and pneumocytic pleural effusion group (60 cases) according to the cause of attack. Two groups of patients given anti-TB or anti-inflammatory and other comprehensive treatment based on the addition of urokinase pleural cavity perfusion therapy, after the end of the evaluation of clinical efficacy. Results Tuberculous pleural effusion group: 41 cases were markedly effective, 20 cases were effective and 2 cases were ineffective, with a total effective rate of 96.83%. In the pneumocystoid pleural effusion group, 36 cases were markedly effective, 17 cases were effective and 7 cases were ineffective , The total effective rate was 88.33%. Two groups of patients have achieved good clinical efficacy, pneumocystoid pleural effusion group was less effective in tuberculous pleural effusion group, the clinical efficacy of the two groups by χ2 test was no significant difference (χ2 = 3.2718, P > 0.05). Conclusions Urokinase pleural cavity infusion can achieve good clinical curative effect in tuberculous or pneumocytic pleural effusion, and there is no significant difference between the two groups.